Cullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on Thursday

Cullinan Therapeutics (NASDAQ:CGEM) is projected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.7993) per share and revenue of $3.6670 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its earnings results on Thursday, May 7th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.09. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Price Performance

Shares of NASDAQ:CGEM opened at $16.89 on Tuesday. The business’s 50-day moving average is $16.43 and its 200 day moving average is $14.63. Cullinan Therapeutics has a 1 year low of $5.68 and a 1 year high of $19.43. The firm has a market capitalization of $1.04 billion, a P/E ratio of -5.03 and a beta of 0.01.

Insider Transactions at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $17.82, for a total value of $142,560.00. Following the completion of the transaction, the insider directly owned 162,844 shares of the company’s stock, valued at approximately $2,901,880.08. The trade was a 4.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

Several large investors have recently made changes to their positions in the company. Schonfeld Strategic Advisors LLC purchased a new position in Cullinan Therapeutics in the fourth quarter valued at $172,000. AlphaCentric Advisors LLC purchased a new stake in shares of Cullinan Therapeutics during the 4th quarter worth about $197,000. Fox Run Management L.L.C. boosted its stake in shares of Cullinan Therapeutics by 36.6% during the 4th quarter. Fox Run Management L.L.C. now owns 21,204 shares of the company’s stock worth $219,000 after acquiring an additional 5,676 shares in the last quarter. Caption Management LLC boosted its stake in shares of Cullinan Therapeutics by 107.0% during the 3rd quarter. Caption Management LLC now owns 28,389 shares of the company’s stock worth $168,000 after acquiring an additional 435,062 shares in the last quarter. Finally, Magnetar Financial LLC acquired a new stake in shares of Cullinan Therapeutics during the 3rd quarter valued at about $156,000. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CGEM has been the topic of a number of research analyst reports. BTIG Research boosted their price target on Cullinan Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Cullinan Therapeutics in a research note on Monday, June 8th. Wedbush reissued an “outperform” rating and set a $37.00 target price on shares of Cullinan Therapeutics in a research report on Thursday, June 11th. Wall Street Zen lowered shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cullinan Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $32.14.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.